A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer

Inclusion Criteria: 1. Age ≥ 18 years; 2. Histological prove of SCC or esophageal adenocarcinoma; 3. T1N1M0, T2N1M0, T3N0M0, T4N0M0, T3N1M0, T4N1M0, qqTqqNM1a stage, according to the TNM system42; 4. Life expectation above 6 months; 5. Inoperable superior, medial, or distal third esophageal cancer, including GE junction tumors, defined as type I and II tumors in the Siewert classification43 (see Appendix B); 6. Performance status 0, 1, or 2, according to the Eastern Cooperative Oncology Group criteria44 (ECOG) (see Appendix C); 7. Creatinine clearance ≥ 60 ml/min, according to the Cockcroft and Gault formula45 (see Appendix D); 8. Adequate body functions, indicated by * Creatinine clearance ≥ 60 ml/min; * Bilirubin, transaminase, alkaline phosphatase, and gamma-GT \< 1,5 x the upper limit of normal; * leucocytes ≥ 3000/μl; * granulocytes ≥ 1500/ μl; * hemoglobin ≥ 9 g/dl; * platelets ≥ 80000/ μl; 9. Adequate calorie ingestion, at the investigator's discretion; 10. He/she must have signed the informed consent form Exclusion Criteria: 1. Previous or planned treatment of esophageal carcinoma with surgery, radiotherapy, chemotherapy, or antineoplastic biological therapy; 2. Presence of active infection; 3. Knowledge of the presence of HIV seropositivity; 4. Presence of severe comorbidities that, in the investigator's opinion, will put the patient at a significantly higher risk or will damage the protocol compliance; 5. Presence of a significant neurological or psychiatric disease, including dementia and seizures, as per the investigator's judgment; 6. History of malignant neoplasm, except for adequately treated skin basal carcinoma or SCC, and cervical carcinoma in situ; 7. Presence of peripheral neuropathy; 8. Knowledge of the presence of hypersensitivity or allergy to drugs that will be administered in this protocol; 9. History of severe allergic reaction; 10. Pregnancy or lactation; 11. Presence of aerodigestive fistula (trachea and/or bronchia); 12. Evident presence of trachea and/or bronchia infiltration by the tumor; 13. Presence of uncontrolled hypercalcaemia ≥ 2.9 mmol/L (or grade \>1, according to the NCI-CTCAE, version 3.0).